ArticleJournal of orthopaedic surgery and research2025
Serum DLX6-AS1 and miR-141-3p as early diagnostic biomarkers and regulators of delayed fracture healing (DFH).
Article in Journal of orthopaedic surgery and research, 2025. The graph could read no effect estimate from its abstract, so it casts no vote on the map. Not yet cited in PubMed.
What it found
Each row is one number read from the abstract, on the scale the paper reported it, with its interval. Left of the dashed line favours the treatment, right favours the comparator. Under each row is the sentence it came from. New to these charts? A ten-minute tutorial.
The abstract states no effect estimate the extractor could read, or names no intervention and outcome on the map, so this paper lights no cell and moves no belief. It is still indexed, cited and linked below.
The trial behind it
Trials whose registry record cites this paper, or whose number appears in the abstract. A trial that started after this paper was published is citing it as background, not reporting it.
Neither the registry nor the abstract names a trial number. If this is a trial report, that itself is worth knowing.
Who cites it
0 citing papers in PubMed.
No citing paper in PubMed yet.
Corrections and comments
PubMed lists nothing against this paper. Absence here is not a guarantee, only a check that was made.
Authors and funding
4 authors.
Funding
No grant is acknowledged in the PubMed record.
Abstract
objectiveDelayed fracture healing (DFH) is a major clinical challenge, and sensitive molecular biomarkers remain lacking. This study focused on the regulatory roles of lncRNA DLX6-AS1 and miR-141-3p in DFH.
methodsA total of 192 patients were enrolled and classified into normal fracture healing (NFH) and DFH groups. Serum samples were analyzed for DLX6-AS1 and miR-141-3p levels via qRT-PCR. Diagnostic value and risk associations were assessed using ROC curves and logistic regression. Human bone marrow mesenchymal stem cells (hBMSCs) were induced to undergo chondrogenic differentiation. Cellular activity including proliferation and apoptosis was measured. Dual-luciferase and rescue assays explored interactions among DLX6-AS1, miR-141-3p, and VEGFA.
resultsDLX6-AS1 expression was notably reduced, whereas miR-141-3p was elevated in DFH patients. Both were identified as independent risk factors for DFH. The combined detection of two RNAs demonstrated excellent diagnostic performance. Functional assays revealed that DLX6-AS1 promoted, while miR-141-3p suppressed, hBMSCs proliferation, survival, and chondrogenic differentiation. DLX6-AS1 bound miR-141-3p through a sponging mechanism. miR-141-3p directly targeted VEGFA, which was reduced in DFH and inversely correlated with miR-141-3p abundance. Mechanistic analysis confirmed that the DLX6-AS1/miR-141-3p/VEGFA axis regulates hBMSCs proliferation, apoptosis, and chondrogenic differentiation of fracture healing.
conclusionDLX6-AS1 and miR-141-3p emerge as independent risk indicators and potential diagnostic biomarkers for DFH. By modulating the miR-141-3p/VEGFA axis, DLX6-AS1 influences chondrocyte differentiation and fracture repair, highlighting this pathway as a viable target.
Indexed as
Identifiers
What Socratic holds
Registered trials
Read under generation 80e0d062 · epoch 390. Bibliography from PubMed, PubMed Central and OpenAlex; grants from NIH RePORTER; trial links from ClinicalTrials.gov; estimates, votes and beliefs from the Socratic graph.